Sjögren's disease & overlap diseases
MicroRNAs (miRNAs) as potential biomarkers for subclinical atherosclerosis in Sjögren’s disease
An erratum to this article was published (RMD Open, 11 Nov 2024 ↗)
Authors' conclusion
In conclusion, patients with SjD demonstrated differences in their expression of miRNAs linked to regulation of endothelial function.
Study context
- Population
- Patients with Sjögren's disease (SjD) and age and sex-matched healthy controls
- Participants
- 199 vs 100
- Comparison
- SjD vs age and sex-matched healthy controls (HC)
- SjDn = 199
- HCn = 100reference
- Outcome
- Serum levels of five endothelial function-associated miRNAs (miR-92a-3p, miR-126-3p, miR-143-3p, miR-145-5p, miR-204-5p) vs HC, and correlation with CV risk factors and cIMT
Methodological detailsage and sex-matched healthy controls, quantitative real-time PCR
- Age and sex-matched healthy controls
- Quantitative real-time PCR
Main finding
As reported in the abstract
Serum miRNA expression, SjD vs HC
- Four miRNAs showed significantly different expressions compared with HC
- SjD vs HC: P = 0.025
- SjD vs HC: P = 0.044
- SjD vs HC: P = 0.006
- SjD vs HC: P = 0.009
Observational data: associations, not effects.
Further findings
miR-92a-3p in SjD with organ involvement vs HC and SjD without organ involvement
- Descriptively increased miR-92a-3p levels in SjD with organ involvement (p=0.087)
Correlation of miR-92a-3p with carotid intima-media thickness (cIMT) (subclinical atherosclerosis)
- Positive correlation, r
- 0.148
- P
- P = 0.04
Original publication
miRNAs as potential biomarkers for subclinical atherosclerosis in Sjögren’s disease. RMD Open. Published 22 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →